Table.
Prevalence and characteristics of primary HIV drug resistance in the UK 1994-2000
| Estimated year of seroconversion | Total tested (No with drug resistance mutations) | Key mutations associated with drug resistance for each patient identified | Drugs for which mutations compromise efficacy |
|---|---|---|---|
| 1994 | 1 (0) | — | — |
| 1995 | 5 (0) | — | — |
| 1996 | 15 (0) | — | — |
| 1997 | 3 (1) | RT: M41L, T215L | Zidovudine |
| 1998 | 10 (1) | RT: M41L, T215Y | Zidovudine |
| 1999 | 9 (1) | RT: M41L | Zidovudine |
| 2000 | 26 (7) | RT: K219Q | Zidovudine |
| RT: T69N | Didanosine, zalcitabine | ||
| RT: Y181C | Nevirapine, efavirenz | ||
| RT: M41L, V108I, T215D* | Zidovudine, efavirenz, nevirapine | ||
| RT: M41L, K103N, Y188L, T215Y | Zidovudine, efavirenz, nevirapine | ||
| PR: L90M | Saquinavir, nelfinavir | ||
| RT: T215D* | Zidovudine |
RT=reverse transcriptase; PR=protease; C=cysteine; D=aspartic acid; I=isoleucine; K=lysine; L=leucine; M=methionine; N=asparagine; Q=glutamine; T=threonine; V=valine; Y=tyrosine.
*
Although the T215D mutation does not itself confer resistance, it reflects evolution from a transmitted zidovudine resistant virus and is prone to re-emergence of resistance following initiation of therapy.7 It has therefore been included in the table.